Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to
evaluate the safety and immune responses in patients who are positive either or both
antigens. Nine patients will be enrolled, who are refractory to standard therapies for cancer
or at high risk to relapse. CHP-HER2 and CHP-NY-ESO-1 are subcutaneously given on bimonthly
basis, together with OK-432(Picibanil) as an immunoadjuvant. Six doses will be given.
Toxicity profiles will be monitored, and antigen specific humoral anad T cell responses will
be described.